Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults

NCT00008554 is registered in ClinicalTrials.gov with Glaxo Wellcome as lead sponsor.

NCT NCT00008554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00008554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults
Lead sponsor
Glaxo Wellcome
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2000
Completion date
Not reported
Enrollment
210
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections